Australia's most trusted
source of pharma news
Thursday, 23 October 2025
Posted 21 October 2025 PM
The TGA has added a new warning to a game changing drug expected to be a blockbuster within a few years, just 15 days before it is considered by the PBAC at its November meeting.
Astellas notified the regulator of a concern with its neurokinin 3 receptor antagonist Veoza, a non-hormone therapy used to treat moderate to severe vasomotor symptoms associated with menopause, otherwise known as hot flushes.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.